-- Interim CEO unanimously chosen to lead global operations in patient-first 
oncology innovation

Sirtex Medical ( 
https://c212.net/c/link/?t=0&l=en&o=2612906-1&h=1386258278&u=http%3A%2F%2Fwww.sirtex.com%2F&a=Sirtex+Medical 
), a leading manufacturer of targeted liver cancer therapies, today announced 
the appointment of Kevin R. Smith as Chief Executive Officer of Sirtex Medical 
Pty Ltd. Sirtex is a global healthcare business with offices and manufacturing 
facilities in the U.S., Australia, Germany and Singapore.

Logo - https://mma.prnewswire.com/media/926923/Sirtex_Medical_Logo.jpg

The Sirtex Board unanimously appointed Smith based on his proven leadership, 
expertise in the healthcare and pharmaceutical space, and accomplishments 
during his tenure at Sirtex.

According to Minfang "Alex" Wu from CDH Investments, Sirtex's majority 
shareholder, Kevin is the ideal fit for the organization. "Kevin brings an 
exceptional background in leadership that we believe will drive the growth of 
Sirtex and lead it to an exciting future that benefits patients and employees."

Prior to his role as Interim CEO of Sirtex, Kevin served as Executive Vice 
President, Sales & Marketing for the Americas, leading Sirtex's business 
development initiatives while implementing a commercial strategy for ongoing 
growth and expansion in Latin America. Earlier this year, Sirtex announced 
delivery of the 100,000th patient dose of SIR-Spheres(R) Y-90 resin 
microspheres, a treatment for patients with liver cancer.*

Forrest Shi, CEO of China Grand Pharmaceutical, Sirtex's other major 
shareholder, comments, "The appointment of Kevin isn't just the choice by the 
Board, but by everyone here at Sirtex. We are extremely confident Sirtex will 
be best served under Kevin's leadership. Based on the partnership we have had 
with Kevin in the past few months, we are very happy to view Sirtex as a 
platform for precision medicine and look forward to the bright future ahead."

"Kevin is a remarkable member of the Sirtex senior leadership team who truly 
embodies our values and appreciates everyone in the Sirtex family," says 
Cathleen Lowndes, Chief Human Resources Officer of Sirtex. "We're thrilled to 
work with Kevin in achieving our mission to improve patients' lives." 

Before joining Sirtex, Kevin was Executive Vice President of Business 
Development at Gel-e, Inc., a startup company based at the University of 
Maryland specializing in advanced material hemostasis products. His previous 
positions include leadership roles at Sensium Medical, Teleflex Medical, 
Hill-Rom, Zoll Medical and Smiths Group.

"I am honored and excited to lead the outstanding team we have at Sirtex as 
Chief Executive Officer," says Kevin. "I look forward to continuing to work 
with our extraordinary senior leadership team, board of directors and extended 
families at CDH and CGP. We are fortunate to have the most talented, global 
organization in our industry. Together, we will maximize the value of Sirtex 
through our patient-first focus, organic growth initiatives, acquisition 
strategy and the best career experiences for our people."

*In the United States, SIR-Spheres Y-90 resin microspheres received Premarket 
Approval (PMA) from the FDA and are indicated for the treatment of 
non-resectable metastatic liver tumors from primary colorectal cancer in 
combination with intrahepatic artery chemotherapy using floxuridine. 
SIR-Spheres Y-90 resin microspheres are approved for the treatment of 
inoperable liver tumors in Australia, the European Union, Argentina, Brazil, 
Canada and several countries in Asia, such as India and Singapore.

About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin 
microspheres
SIR-Spheres Y-90 resin microspheres is a prescription device for the treatment 
of inoperable liver tumors. It is a minimally invasive treatment that delivers 
high doses of high-energy beta radiation directly to the tumors. SIRT is 
administered to patients by interventional radiologists, who infuse millions of 
radioactive resin microspheres via a catheter into the liver arteries that 
supply blood to the tumors. By using the tumors' blood supply, the microspheres 
selectively target liver tumors with a dose of radiation that is up to 40 times 
higher than conventional radiotherapy, while sparing healthy tissue.

About Sirtex
Sirtex Medical is a global healthcare business with offices in the U.S., 
Australia, Germany and Singapore, working to improve outcomes in people with 
cancer. Our current lead product is a targeted radiation therapy for liver 
cancer called SIR-Spheres Y-90 resin microspheres. More than 100,000 doses have 
been supplied to treat patients with liver cancer at more than 1,000 medical 
centers in over 40 countries. For more information, visit www.sirtex.com.

SIR-Spheres(R) is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

DOC ID: #286-EUA-1019

SOURCE: Sirtex Medical

CONTACT: Elizabeth Comtois, Phone: +1 (919) 334-3786, Email: 
elizabeth.comtois@fleishman.com